Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $222
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $222.
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $222.